A major clinical trial in Canada shows that an inexpensive anti-inflammatory drug called colchicine can significantly reduce the risk of complications and death from COVID-19, bringing “important hope” to sufferers, the lead researcher said Sunday. Jean-Claude Tardif, head of the Montreal Heart Institute (ICM), led the study named “Colcorona,” whose preliminary results were published Friday